Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
725 Views
eMediNexus 19 December 2017
The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a paediatric-use marketing authorisation for Alkindi (hydrocortisone) for the treatment of primary adrenal insufficiency, a rare hormonal disorder, in infants, children and adolescents.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
How Anemia Types Alter HbA1c Values..
Optimizing Glycemic Control in GDM: Continuous Glucose Monitoring Vs C.....
Factors Driving the Atopic March in Children with Early-Onset Atopic .....
Metabolic Health: Another Piece in the Parkinson Puzzle?..
High Remnant Cholesterol and Risk of Gestational Diabetes..
{{Article_Title}}..
South Asian Nations Push for Collaborative Public Health Research..
Health Ministry Mandates Excipient Disclosure on Drug Labels from 2026..
Israel to Perform World's First Human Spinal Cord Implant..
Madras High Court Seeks Report On Kidney Trafficking Racket in Tamil Nadu..
ICMR Study Shows Nutrition Support Cuts TB Risk, Influences WHO Policy..